title: [Efficacy and safety of low-dose high intensity focused ultrasound combined with S-1 and oxaliplatin in metastatic colorectal patients with pelvic masses].
abstract: OBJECTIVE
  To evaluate the efficacy and safety of the regimen of low-dose high intensity focused ultra-sound (HIFU) plus S-1 and oxaliplatin (SOX) in the treatment of metastatic colorectal cancer patients with pelvic masses.
  
  
  METHODS
  A total of 46 patients with metastatic colorectal cancer were recruited and divided into 2 groups: Twenty patients received concurrent HIFU plus S-1 and oxaliplatin (SOX) while another 26 patients SOX alone. The baseline characteristics, progressive-free survival, overall survival time and adverse events were retrospectively analyzed.
  
  
  RESULTS
  The median PFS was 11.2 months (95% CI 9.8-12.7) in the HIFU+SOX group and 7.1 months (95% CI 5.8-8.4) in the SOX group (P = 0.003). And the overall survival time in two groups were 21.9 months (95% CI 18.0-25.9) and 16.9 months (95%CI 14.1-19.6) (P = 0.072) respectively. Major toxic effects included grade 3/4 neutropenia (15%), anemia (10%), thrombocytopenia (10%), diarrhea (15%) and hand-foot syndrome (10%) in the HIFU+SOX group. And it showed no statistically significant differences with the SOX group.
  
  
  CONCLUSIONS
  The combined regimen of HIFU and SOX is effective and well-tolerated in patients of late-stage colorectal cancer with pelvic masses.
authors.affiliation: Department of Interventional Therapy, Cancer Hospital, Tianjin Medical University, Tianjin 300060, China.
authors.forename: Lili
authors.initials: L
authors.lastname: Hong
authors.affiliation: Department of Interventional Therapy, Cancer Hospital, Tianjin Medical University, Tianjin 300060, China. Email:cjr.guozhi@vip.163.com.
authors.forename: Zhi
authors.initials: Z
authors.lastname: Guo
authors.affiliation: Department of Interventional Therapy, Cancer Hospital, Tianjin Medical University, Tianjin 300060, China.
authors.forename: Haipeng
authors.initials: H
authors.lastname: Yu
authors.affiliation: Department of Interventional Therapy, Cancer Hospital, Tianjin Medical University, Tianjin 300060, China.
authors.forename: Baoguo
authors.initials: B
authors.lastname: Li
authors.affiliation: Department of Interventional Therapy, Cancer Hospital, Tianjin Medical University, Tianjin 300060, China.
authors.forename: Tongguo
authors.initials: T
authors.lastname: Si
authors.affiliation: Department of Interventional Therapy, Cancer Hospital, Tianjin Medical University, Tianjin 300060, China.
authors.forename: Changfu
authors.initials: C
authors.lastname: Liu
mesh_terms: D000740:Anemia; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004338:Drug Combinations; D006801:Humans; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D010094:Oxonic Acid / Q000008:administration & dosage; D010386:Pelvic Neoplasms / Q000000981:diagnostic imaging* / Q000556:secondary; D012189:Retrospective Studies; D005641:Tegafur / Q000008:administration & dosage; D013921:Thrombocytopenia; D016896:Treatment Outcome; D014463:Ultrasonography
chemical_list: D004338:Drug Combinations; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid